Cartesian Therapeutics Stock Performance

RNAC Stock   6.28  0.56  8.19%   
The firm shows a Beta (market volatility) of 0.55, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Cartesian Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Cartesian Therapeutics is expected to be smaller as well. At this point, Cartesian Therapeutics has a negative expected return of -0.25%. Please make sure to confirm Cartesian Therapeutics' skewness, as well as the relationship between the daily balance of power and day typical price , to decide if Cartesian Therapeutics performance from the past will be repeated at some point in the near future.

Risk-Adjusted Performance

Weakest

 
Weak
 
Strong
Over the last 90 days Cartesian Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain rather sound which may send shares a bit higher in March 2026. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders. ...more

Actual Historical Performance (%)

One Day Return
(8.19)
Five Day Return
(9.38)
Year To Date Return
(7.10)
Ten Year Return
(98.50)
All Time Return
(98.50)
Last Split Factor
1:30
Last Split Date
2024-04-05
1
Disposition of 7500 shares by Emily English of Cartesian Therapeutics at 3.3 subject to Rule 16b-3
11/28/2025
2
Acquisition by Springer Timothy A of 5181 shares of Cartesian Therapeutics at 18.9996 subject to Rule 16b-3
12/05/2025
3
Cartesian Therapeutics Sees Share Boost After Insider Pur - GuruFocus
12/09/2025
4
Insider Trading
12/16/2025
5
Aug Wrap Why Cartesian Therapeutics Inc. stock could be top winner - Weekly Gains Summary Daily Volume Surge Trade Alerts - DonanmHaber
12/19/2025
6
Acquisition by Kalayoglu Murat of 7800 shares of Cartesian Therapeutics at 6.76 subject to Rule 16b-3
01/02/2026
7
Top Brass Makes Big Moves as Cartesian Therapeutics Executives Cash In on Shares - TipRanks
01/08/2026
8
Cartesian Therapeutics, Inc. Upgraded to Buy What Does It Mean for the Stock
01/14/2026
9
Cartesian Therapeutics, Inc. Stock Analysis Can a 388.62 percent Upside Fuel Your Investment Strategy - DirectorsTalk Interviews
01/29/2026
10
Cartesian Therapeutics Issues New Stock Options to Employ - GuruFocus
02/03/2026
Begin Period Cash Flow78.3 M
Total Cashflows From Investing Activities-8.7 M

Cartesian Therapeutics Relative Risk vs. Return Landscape

If you would invest  787.00  in Cartesian Therapeutics on November 7, 2025 and sell it today you would lose (159.00) from holding Cartesian Therapeutics or give up 20.2% of portfolio value over 90 days. Cartesian Therapeutics is currently does not generate positive expected returns and assumes 5.0089% risk (volatility on return distribution) over the 90 days horizon. In different words, 45% of stocks are less volatile than Cartesian, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Expected Return   
       Risk  
Given the investment horizon of 90 days Cartesian Therapeutics is expected to under-perform the market. In addition to that, the company is 6.55 times more volatile than its market benchmark. It trades about -0.05 of its total potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.09 per unit of volatility.

Cartesian Therapeutics Target Price Odds to finish over Current Price

The tendency of Cartesian Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 6.28 90 days 6.28 
about 98.0
Based on a normal probability distribution, the odds of Cartesian Therapeutics to move above the current price in 90 days from now is about 98.0 (This Cartesian Therapeutics probability density function shows the probability of Cartesian Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days Cartesian Therapeutics has a beta of 0.55 indicating as returns on the market go up, Cartesian Therapeutics average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Cartesian Therapeutics will be expected to be much smaller as well. Additionally Cartesian Therapeutics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial.
   Cartesian Therapeutics Price Density   
       Price  

Predictive Modules for Cartesian Therapeutics

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Cartesian Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Hype
Prediction
LowEstimatedHigh
1.396.4011.41
Details
Intrinsic
Valuation
LowRealHigh
5.6513.5018.51
Details
Naive
Forecast
LowNextHigh
0.795.7910.80
Details
8 Analysts
Consensus
LowTargetHigh
32.3735.5739.48
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Cartesian Therapeutics. Your research has to be compared to or analyzed against Cartesian Therapeutics' peers to derive any actionable benefits. When done correctly, Cartesian Therapeutics' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Cartesian Therapeutics.

Cartesian Therapeutics Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Cartesian Therapeutics is not an exception. The market had few large corrections towards the Cartesian Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Cartesian Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Cartesian Therapeutics within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
-0.31
β
Beta against Dow Jones0.55
σ
Overall volatility
0.53
Ir
Information ratio -0.07

Cartesian Therapeutics Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Cartesian Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Cartesian Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Cartesian Therapeutics generated a negative expected return over the last 90 days
Cartesian Therapeutics has high historical volatility and very poor performance
The company reported the previous year's revenue of 38.91 M. Net Loss for the year was (77.42 M) with loss before overhead, payroll, taxes, and interest of (51.76 M).
Cartesian Therapeutics currently holds about 106.44 M in cash with (23.67 M) of positive cash flow from operations.
Cartesian Therapeutics has a poor financial position based on the latest SEC disclosures
Roughly 61.0% of the company outstanding shares are owned by corporate insiders
Latest headline from news.google.com: Cartesian Therapeutics Issues New Stock Options to Employ - GuruFocus

Cartesian Therapeutics Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Cartesian Stock often depends not only on the future outlook of the current and potential Cartesian Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Cartesian Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding23.7 M
Cash And Short Term Investments212.6 M

Cartesian Therapeutics Fundamentals Growth

Cartesian Stock prices reflect investors' perceptions of the future prospects and financial health of Cartesian Therapeutics, and Cartesian Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Cartesian Stock performance.

About Cartesian Therapeutics Performance

By analyzing Cartesian Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Cartesian Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Cartesian Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Cartesian Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.38)(0.40)
Return On Capital Employed(0.10)(0.10)
Return On Assets(0.16)(0.17)
Return On Equity 10.24  10.76 

Things to note about Cartesian Therapeutics performance evaluation

Checking the ongoing alerts about Cartesian Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Cartesian Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Cartesian Therapeutics generated a negative expected return over the last 90 days
Cartesian Therapeutics has high historical volatility and very poor performance
The company reported the previous year's revenue of 38.91 M. Net Loss for the year was (77.42 M) with loss before overhead, payroll, taxes, and interest of (51.76 M).
Cartesian Therapeutics currently holds about 106.44 M in cash with (23.67 M) of positive cash flow from operations.
Cartesian Therapeutics has a poor financial position based on the latest SEC disclosures
Roughly 61.0% of the company outstanding shares are owned by corporate insiders
Latest headline from news.google.com: Cartesian Therapeutics Issues New Stock Options to Employ - GuruFocus
Evaluating Cartesian Therapeutics' performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Cartesian Therapeutics' stock performance include:
  • Analyzing Cartesian Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Cartesian Therapeutics' stock is overvalued or undervalued compared to its peers.
  • Examining Cartesian Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Cartesian Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Cartesian Therapeutics' management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of Cartesian Therapeutics' stock. These opinions can provide insight into Cartesian Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Cartesian Therapeutics' stock performance is not an exact science, and many factors can impact Cartesian Therapeutics' stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.

Complementary Tools for Cartesian Stock analysis

When running Cartesian Therapeutics' price analysis, check to measure Cartesian Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cartesian Therapeutics is operating at the current time. Most of Cartesian Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cartesian Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cartesian Therapeutics' price. Additionally, you may evaluate how the addition of Cartesian Therapeutics to your portfolios can decrease your overall portfolio volatility.
Global Correlations
Find global opportunities by holding instruments from different markets
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Commodity Directory
Find actively traded commodities issued by global exchanges
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios